**USE OF PALIVIZUMAB IN THE IMMUNOPROFILAXIS OF RESPIRATORY SYNCYTIAL VIRUS**

Marín M, Alzueta N, Pío M, Gascón A.
Hospital Reina Sofía (Tudela). Servicio Navarro de Salud-Osasunbidea.

**BACKGROUND**
Palivizumab is a monoclonal antibody that provides passive immunity against respiratory syncytial virus (RSV).

**PURPOSE**
To evaluate the use of palivizumab as immunoprophylaxis against RVS in the 2016-2017 campaign in a tertiary hospital.

**MATERIAL AND METHODS**
Retrospective observational study (October 2016-March 2017) Patients who received palivizumab as immunoprophylaxis against RSV

Prescription criteria established by *Spanish Society of Neonatology (SEN)*:

- **A**: Children <2 years with bronchopulmonary disease
- **B**: Children <2 years and congenital heart disease
- **C**: Gestational age <28 weeks and age <12 months
- **D**: Gestational age 29-32 weeks and age <6 months
- **E**: Gestational age 32-35 weeks and age <10 weeks and brother/sister of school age

Rapid Antigen-Based Testing for RVS was done

**RESULTS**

20 patients
Sex: 55% male
Age: 6.8 (5.12) months
Mean dose (SD): 93.10 (31.10) mg
Mean administrations (SD): 2.1 (0.75)

1 patient (0.05%) was hospitalized
Diagnostic: Bronchiolitis
RSV test: +
Palivizumab doses: 1

**PRESCRIPTION CRITERIA ESTABLISHED BY SEN**

- **E**: 30%
- **A**: 30%
- **B**: 30%
- **D**: 10%

TOTAL COST: 42,528.9 euros

**CONCLUSIONS**

- Palivizumab has been effective in the prevention of RSV bronchiolitis in high-risk patients
- In all cases it has been used under the criteria established by the SEN. More studies are needed to assess the effectiveness with these criteria.
- According to the results obtained we shall proceed to the establishment of an action protocol for the next vaccination campaign in the hospital.